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The complement system is readily triggered by the presence of damage-associated
molecular patterns on the surface of tumor cells. The complement alternative pathway
provides rapid amplification of the molecular stress signal, leading to complement
cascade activation to deal with pathogens or malignant cells. Properdin is the only
known positive regulator of the alternative pathway. In addition, properdin promotes the
phagocytic uptake of apoptotic T cells by macrophages and dendritic cells without
activating the complement system, thus, establishing its ability to recognize “altered-self”.
Dysregulation of properdin has been implicated in substantial tissue damage in the host,
and in some cases, chronic unresolved inflammation. A corollary of this may be the
development of cancer. Hence, to establish a correlation between properdin presence/
levels in normal and cancer tissues, we performed bioinformatics analysis, using
Oncomine and UALCAN. Survival analyses were performed using UALCAN and
PROGgeneV2 to assess if properdin can serve as a potential prognostic marker for
human lung adenocarcinoma (LUAD), liver hepatocellular carcinoma (LIHC), cervical
squamous cell carcinoma (CESC), and pancreatic adenocarcinoma (PAAD). We also
analyzed levels of tumor-infiltrating immune cells using TIMER, a tool for characterizing
immune cell composition in cancers. We found that in LUAD and LIHC, there was a lower
expression of properdin in the tumors compared to normal tissues, while no significant
difference was observed in CESC and PAAD. Survival analysis demonstrated a positive
association between properdin mRNA expression and overall survival in all 4 types of
cancers. TIMER analysis revealed that properdin expression correlated negatively with
tumor purity and positively with levels of infiltrating B cells, cytotoxic CD8+ T cells, CD4+
helper T cells, macrophages, neutrophils and dendritic cells in LUAD, CESC and PAAD,
and with levels of B cells, CD8+ T cells and dendritic cells in LIHC. Immunohistochemicalorg January 2021 | Volume 11 | Article 6149801
Mangogna et al. Properdin and Cancer Prognosis
Frontiers in Immunology | www.frontiersin.analysis revealed that infiltrating immune cells were the most likely source of properdin in
the tumor microenvironment. Thus, complement protein properdin shows promise as a
prognostic marker in cancer and warrants further study.Keywords: properdin, innate immunity, bioinformatics, cancer, complement, prognosisINTRODUCTION
Properdin, a ~50 kDa glycoprotein found at 4–25 mg/ml level in
plasma, is the only known positive regulator of the complement
system (1, 2). The complement system is an integral part of the
innate immune system. It consists of three pathways, based on the
recognition subcomponents as well as pathogen-associated
molecular patterns (PAMPs) or danger-associated molecular
patterns (DAMPs) on activators such as pathogens and IgG/IgM
(3). The complement classical pathway is triggered by C1q
interaction with IgG/IgM bound to target ligands; the lectin
pathway, a homolog of the classical pathway, is triggered by the
binding of mannan-binding lectin (MBL) to the carbohydrate
patterns on the pathogen surface (4, 5). The complement
alternative pathway is triggered by the spontaneous hydrolysis of
complement proteinC3 intoC3(H2O) (6, 7), which in the presence
of surface PAMPs, binds to the zymogen form of Factor B to form
the fluid-phase C3 proconvertase, C3(H2O)B (8). Factor B is then
cleaved by the serine protease, Factor D, into fragments Ba and Bb;
Bb remains bound to C3(H2O) non-covalently producing C3
(H2O)Bb, which is stabilized by binding to properdin yielding C3
(H2O)BbP, the alternative pathway fluid-phase C3 convertase (2).
C3(H2O)Bb further cleaves additional molecules of C3 into C3a
andC3b (2);C3b gets depositedon thepathogen cell surface,where
it associates with Factor B to generate C3bB, the membrane-
bound C3 proconvertase (4). Factor D then cleaves Factor B in
the C3bB complex and binds to properdin to generate the
membrane-bound C3 convertase, C3bBbP (4), which cleaves
several C3 molecules, leading to C3b deposition on the pathogen
surface (9). C3b deposition is essential for opsonisation while the
chemoattractant, C3a, helps mount an inflammatory response (9).
Additionally, C3b also associates with C3bBb and properdin,
forming the C5 convertase, C3bBbP3b (10) that cleaves C5 into
C5a (a potent chemoattractant) and C5b. C5b sequentially binds
C6, C7, C8 and multiple molecules of C9 to form the membrane
attack complex (MAC) (10). TheMACdisrupts the cellmembrane
of the pathogen causing cell lysis (11–13).
The alternative pathway is tightly regulated by the
interactions of Factor H, C3b and properdin. In the presence
of polyanionic markers that are present on “Self” cells, Factor H
binds to their surface and dissociates Bb from the proconvertase
(C3bBb and C3(H2O)Bb), thereby accelerating the decay of the
convertases (2, 14). Structural analysis of properdin has revealed
that it can interfere with this decay activity of Factor H (15).
Factor H also prevents the formation of new convertases by
playing a role as a cofactor for Factor I-mediated cleavage of C3b
to “inactive” C3b (iC3b) and C3(H2O) to iC3(H2O) (4, 16). This
cofactor activity has also been shown to be limited by properdin
(17, 18). Properdin has also been shown to trigger the alternativeorg 2pathway by directly recruiting C3b or C3(H2O) and Factor B
(19). Properdin is found in circulation as cyclic dimers, trimers
and tetramers in a 26:54:20 ratio via head-to-tail association of
its monomers; it can interact with surface-bound iC3b, C3b and
C3bBb with increasing efficiency (1, 17, 20).
Properdin is locally produced in secondary granules of
stimulated peripheral blood neutrophils, dendritic cells and
T cells (21–25). In addition to the C3 convertase-stabilizing
function, properdin can also act as a humoral pattern recognition
receptor (PRR) for ligands such as lipopolysaccharide, acetylated
low-density lipoprotein, and zymosan (2). Surface bound
properdin has also been shown to activate the alternative
pathway by recruiting C3b and factor B to form C3bBbP (19).
Properdin deficiency, an X-chromosomal recessive trait, is
associated with ~250-fold more susceptibility to Neisseria
meningitidis infection (26). In the case of non-infectious
diseases such as rheumatoid arthritis, patients show decreased
levels of properdin, C3 and C5, but high levels of Ba and C3d in
the synovial fluid (27). Recent demonstration of properdin’s
complement-independent functions as a PRR and modulator of
pro-inflammatory immune response have suggested its
important roles beyond the upregulation of the complement
alternative pathway (28, 29).
Macrophages derived from properdin knockout mice showed
a shift to M2 phenotype, with increased type II cellular immune
responses and decreased MHC class II expression (30). The lack
of properdin has also been shown to protect the host from an
aggravated inflammatory response, increasing the survival of
properdin gene knock-out mice compared to wild type mice (31–
34). In colitis models, properdin deficiency intensified colonic
injury, and more severe renal injury was reported in the presence
of a dysfunctional Factor H and low properdin levels (35, 36).
Properdin has also been reported to promote the uptake of
apoptotic cells by phagocytes (37, 38).
Since properdin is a modulator of pro-inflammatory response
and ~80%–90% of the terminal pathway is activated by the
alternative pathway, the role of properdin in malignancy has
been recently examined. Analysis of 13,023 genes for mutations
between primary breast tumors and normal tissue revealed
mutations at a significant frequency in the properdin (CFP)
gene (39), hinting at mutants contribution to tumor progression
(40). The tumorigenic consequences of dysregulated alternative
pathway has been reaffirmed by a recent study that showed that
aging factor H-deficient mice spontaneously develop hepatic
tumor (~50% of male mice) (41); an increased expression of
Factor H mRNA seemed associated with improved survival in
hepatocellular carcinoma patients (41).
Here, we analyzed properdin expression and its correlation
with prognosis using databases (Oncomine, UALCAN andJanuary 2021 | Volume 11 | Article 614980
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hepatocellular carcinoma (LIHC), cervical squamous cell
carcinoma (CESC), and pancreatic adenocarcinoma (PAAD),
and interrogated if properdin could be an independent marker
for diagnosis and a surrogate marker of severity and overall
survival. Moreover, we investigated the correlation of properdin
with tumor-infiltrating immune cells (TIICs) in all 4 types of
cancers via Tumor IMmune Estimation Resource (TIMER) and
performed immunohistochemical analysis to identify the most
likely sources of properdin in the tumor microenvironment.MATERIALS AND METHODS
Gene Expression and Survival Analysis
The expression levels of CFP gene in different carcinomas
were analyzed using Oncomine (www.oncomine.org) and
UALCAN (http://ualcan.path.uab.edu). Oncomine is a cancer
microarray database and web-based data mining platform fromFrontiers in Immunology | www.frontiersin.org 3thegenome-wideexpressionanalyses.UALCAN, inaddition tobeing
aweb resource for analyzing cancer transcriptomedata, estimates the
effects of gene expression levels on the patient survival (42–44). We
compared the differences in mRNA levels between carcinomas and
normal tissues. ThemRNAexpression levels in theneoplastic tissues,
as compared to healthy tissues, were obtained as parameters of p-
value<0.05, foldchange>2, andgeneranking in the top10%.Further
information about the datasets can be found in Table 1.
The prognostic significance of CFP mRNA expression with
respect to survival in carcinomas was analyzed by UALCAN,
using genomic data from “The Cancer Genome Atlas” (TCGA)
to generate survival probability plots in the given carcinomas via
Kaplan–Meier survival analysis (44). Additional survival
analyses were performed with PROGgeneV2 (www.genomics.
jefferson.edu/proggene/index.php) using data from TCGA (45,
46). Hazard ratio with a 95% confidence interval and log-rank p-
value were also computed. In order to evaluate the prognostic
effect of properdin, the four carcinomas we considered were
LUAD, LIHC, CESC and PAAD.TABLE 1 | Characteristics of the datasets used in bioinformatics analysis.
Datasets Study Description Experiment
Type





226 lung adenocarcinoma samples and 20 normal lung tissues were analyzed. Sample data includes EGFR mutation, KRAS mutation,




139 lung adenocarcinoma, 21 squamous cell lung carcinoma, 20 lung carcinoid tumor, six small cell lung carcinoma, and 17 normal lung
samples were analyzed on Affymetrix U95A microarrays. Sample data includes type, age, M stage, max tumor percentage, N stage,
primary/metastatic, recurrence, sex, site of metastasis, smoking rate (packs per year), stage, survival, and T stage.
mRNA
Su Lung 91 non-small cell lung carcinoma and 65 adjacent normal lung samples were analyzed. Sample data includes age, sex, cancer sample
site, and survival.
mRNA
TCGA Lung 503 squamous cell lung carcinoma samples and 515 lung adenocarcinoma samples were analyzed on a custom Agilent microarray.
Sample data includes age, TNM stage, sex, survival, smoking status, and others. This dataset is a combination of Lung Adenocarcinoma
[LUAD] and Lung Squamous Cell Carcinoma [LUSC] data from the TCGA data portal and consists of Level 2 (processed) data.
mRNA
Roessler Liver 225 hepatocellular carcinoma and 220 normal liver samples were analyzed. mRNA
Roessler 2
Liver
22 hepatocellular carcinoma, 19 normal liver, and two pooled normal liver tissue samples were analyzed. mRNA
Wurmbach
Liver
75 liver tissue samples were analyzed on Affymetrix U133 Plus 2.0 microarrays. This set of samples represents the stepwise
carcinogenic process from preneoplastic lesions to hepatocellular carcinoma, in the following order: Normal Liver (n=10), Cirrhotic Liver
(n=13), Dysplastic Liver (n=17), and Hepatocellular Carcinoma (n=35). All non-normal samples were hepatitis virus C (HCV) positive, but
negative for other known causal agents of hepatocellular cancer. Sample data includes HCC stage, tumor size, differentiation, vascular
invasion, and satellites.
mRNA
TCGA Liver 371 hepatocellular carcinoma, 56 paired normal blood, and 59 paired normal liver tissue samples were analyzed. Sample data includes
sex, TNM stage, race/ethnicity, and others. This dataset consists of Level 3 data (segmented using CBS) from the TCGA data portal.
The resulting segments were mapped to RefSeq gene coordinates as provided by UCSC. The samples were originally run on the
Affymetrix SNP 6.0 platform.
mRNA
TCGA Cervix 305 cervical squamous cell carcinoma, 95 paired blood derived normal, and three paired normal cervix tissue samples were analyzed.
Sample data includes age, TNM stage, grade, FIGO stage, survival and others. This dataset consists of Level 3 data (segmented using
CBS) from the TCGA data portal. The resulting segments were mapped to RefSeq gene coordinates as provided by UCSC. The




178 pancreatic adenocarcinoma, 17 pancreatic ductal adenocarcinoma, one colloid carcinoma of the pancreas, 42 normal blood, and
eight normal pancreas tissue samples were analyzed. This dataset consists of Level 3 data (segmented using CBS) from the TCGA data
portal. The resulting segments were mapped to RefSeq gene coordinates as provided by UCSC. The samples were originally run on the
Affymetrix SNP 6.0 platform.
mRNAJanuary 2021 | Volume 11 | Article 614980
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The differential protein expression of properdin between
carcinoma and normal tissues was analyzed via UALCAN,
which allowed protein expression analysis using the
Clinical Proteomic Tumor Analysis Consortium (CPTAC)
Confirmatory/Discovery dataset (47).
TIMER Database Analysis
TIMER is a comprehensive resource for systematic analysis of
immune infiltrates across diverse cancer types (www.cistrome.
shinyapps.io/timer) (48). TIMER applies a statistical method to
infer the abundance of TIICs from the gene expression profiles
using TCGA dataset (49). We analyzed, in LUAD, LIHC, CESC,
PAAD, the correlation between CFP expression and the
abundance of immune infiltrates, such as B cells, CD4+ T cells,
CD8+ T cells, neutrophils, macrophages, and dendritic cells,
via gene modules (50–52). The correlation module generated
the expression scatter plots between the CFP gene and
defined genes of TIICs in selected carcinomas, together with
the Spearman’s correlation and the estimated statistical
significance. CFP was plotted on the x-axis and the related
marker genes were represented on the y-axis as genes of TIICs.
The gene expression level was displayed with log2 RNA-Seq by
Expectation-Maximization (RSEM).
Immunohistochemical Analysis
Surgical normal tissue samples of lung, liver, uterine cervix and
pancreas along with their malignant counterparts were selected
for immunohistochemical analysis for properdin expression.
Invasive malignant neoplasma specimens included the
histotypes- LUAD, LIHC, CESC, and PAAD. The study was
approved by the Institutional review board of the University
of Palermo (09/2018). A specific informed consent was
not required at the time of tissue sample collection for the
immunohistochemical analysis of archival tissue sections since
the patients were not identified and genetic analysis was not
carried out. Immunohistochemistry (IHC) was performed using
a polymer detection method. Briefly, tissue samples were fixed
in 10% (v/v) neutral buffered formalin and then paraffin
embedded. Tissue sections (4 mm thick) were deparaffinized
and rehydrated. The antigen unmasking technique was carried
out using Novocastra Epitope Retrieval Solutions, pH 9 (Leica
Biosystems) in thermostatic bath at 98°C for 30 min. Sections
were then brought to room temperature and washed in PBS.
After neutralization of the endogenous peroxidase with 3% (v/v)
H2O2 and Fc blocking by a specific protein block (Novocastra,
Leica Biosystems), samples were incubated for 1 h at room
temperature with mouse anti-human properdin (Clone C-4,
1:50, Santa Cruz) monoclonal antibody. Staining was
revealed using Novolink Polymer Detection System
(Novocastra, Leica Biosystems) and Romulin AEC Chromogen
Kit (BioCare) as substrate chromogen, following the
manufacturer’s instructions. Slides were counterstained with
Harris Hematoxylin (BioOptica). Slides were analyzed under
the Axio Scope A1 optical microscope (Zeiss) andFrontiers in Immunology | www.frontiersin.org 4microphotographs were collected through the Axiocam 503
color digital camera (Zeiss) using the Zen2 software.
Statistical Analysis
Survival curveswere generated byUALCANand/or PROGgeneV2.
All results were displayed with p-values from a log-rank test. p-
values < 0.05 were considered significant (53, 54). Similarly, in the
case of Oncomine, the program provided the statistical significance
of the data (p-values). In TIMER, the correlation of gene expression
was evaluated by Spearman’s correlation and statistical
significance, and the strength of the correlation was determined
using the following guide for the absolute value: 0.00-0.19: very
weak; 0.20-0.39: weak; 0.40-0.59: moderate; 0.60-0.79: strong; and
0.80-1.0: very strong.RESULTS
Lower Properdin Expression Correlates
With Poor Prognosis in Lung
Adenocarcinoma and Vice Versa
We initially evaluated the differences in the mRNA level of
properdin in LUAD as compared to normal lung tissue, using
the Oncomine platform via Hou’s, Okayama’s, Su’s and
Bhattacharjee’s datasets (Table 1). We noted a significantly
lower properdin mRNA expression in LUAD in comparison
with healthy lung tissue counterpart (p < 0.05) (Figures 1A–D).
Similar result was revealed by UALCAN tool analysis using the
TCGA dataset (p < 0.05) (Figure 1E). UALCAN proteomics
analysis also validated lower expression of properdin in LUAD,
as compared to the corresponding healthy tissue (p < 0.05)
(Figure 1F). As shown in Figure 2A, properdin mRNA
expression positively correlated with the overall survival (OS)
rate of LUAD patients (p < 0.05). Based on the TIMER analysis,
CFP expression showed a significantly weak negative correlation
with tumor purity (p < 0.05). It revealed a partial but significant
and positive correlation with infiltrating levels of B cells, CD8+ T
cells, CD4+ T cells, macrophages, neutrophils and dendritic cells
(p < 0.05) (Figure 2B). The strength of the correlation was very
weak for CD8+ T cells, whereas it was relatively weaker for B
cells, CD4+ T cells, macrophages, neutrophils and dendritic cells.
In lung IHC staining, with membrane as well as cytoplasmic
labeling, properdin was found to be expressed mainly by the
alveolar macrophages in a diffuse pattern; endothelial cells
labeled mildly (Figures 3A, B). In LUAD, we observed
properdin expression within the tumor-associated immune
infiltrates (Figures 3C, D). Properdin positive cells were
mainly represented by macrophages and somewhat minimally
by granulocytes, present within the tumoral nests as well as in the
intratumoral stromal microenvironment. Moreover, the density
of properdin positive cells showed a variable distribution in the
neoplastic tissue; in fact, it was higher in the inter-tumoral
stroma compared to the one detected in the neoplastic
proliferation. Thus, the immunohistochemical assessment
confirmed that the immune cells were the main source
of properdin.January 2021 | Volume 11 | Article 614980
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Hepatocellular Carcinoma Correlates
Positively With Overall Survival and
Immune Infiltration in the Tumor
Microenvironment
Bioinformatics analysis of properdin mRNA expression was
performed in the context of the LIHC using the Roessler, Roessler
2, Wurmbach and TCGA dataset. Similar to LUAD, a lower
expression level of properdin was detected as compared to normal
liver tissue (p < 0.05) (Figure 4). According to UALCAN tool,
properdin mRNA expression positively associated with an OS rate
inLIHCpatients (p<0.05) (Figure 5A).A significant andmoderate
negative correlation between properdin expression and tumor
purity was also observed (p < 0.05) (Figure 5B). It showed partial
but significant and positive correlations with infiltrating levels of B
cells, CD8+ T cells and dendritic cells (p < 0.05). The strength of the
correlation was very weak for B cells and dendritic cells, whereas itFrontiers in Immunology | www.frontiersin.org 5was weak for CD8+ T cells. No significant correlation between the
infiltrating levels ofCD4+T cells,macrophages andneutrophils and
CFP expression was noted in LIHC.
The IHC staining of liver parenchyma for properdin
highlighted a variable pattern: ~30%–40% of hepatocytes
exhibited cytoplasmic expression of properdin. A few immune
infiltrates normally present within the portal space and in the
portal stroma also showed properdin positivity (Figures 6A, B).
In LIHC, immunohistochemical staining revealed properdin
expression in the TIICs within the stromal microenvironment
as well as a few neoplastic components (~2% of total tumor cells)
(Figures 6C, D).
Properdin Is Expressed in Cervical
Squamous Cell Carcinoma and Normal
Cervical Tissues at Similar Levels
No significant difference regarding properdin expression level in




FIGURE 1 | Properdin expression in lung adenocarcinoma. (A–E) In silico analysis of properdin (CFP) gene expression in lung adenocarcinoma (LUAD). CFP gene
expression from Hou Lung (A), Okayama Lung (B), Su Lung (C), and Bhattacharjee Lung (D) datasets plotted by Oncomine and The Cancer Genome Atlas (TCGA)
Lung (E) dataset plotted by UALCAN tool revealed a decrease in properdin mRNA expression in the adenocarcinoma tissues when compared to the healthy lung tissues.
In silico analysis of properdin (CFP) protein expression using CPTAC Confirmatory/Discovery (F) dataset analyzed using UALCAN confirmed higher levels of properdin in
healthy tissues compared to the cancerous tissues, similar to the gene expression studies.January 2021 | Volume 11 | Article 614980
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FIGURE 2 | Prognostic value of properdin in lung adenocarcinoma. (A) An association between CFP expression and overall survival. Overall Survival (OS) of lung
cancer patients expressing high [red] (n=125) and low/medium [blue] (n=377) levels of properdin over a period of ~7,000 days (~19 years) analyzed with Kaplan–
Meier survival. Analysis using The Cancer Genome Atlas (TCGA) Lung dataset by UALCAN revealed that patients with high levels of properdin expression have had a
significant improvement in survival compared to their low/medium expression counterparts. (B) The correlation of CFP gene expression with immune infiltration level
in lung adenocarcinoma. Levels of tumor-infiltrating immune cells in the lung adenocarcinoma were analyzed from TCGA Lung dataset using TIMER. CFP expression
was found to be significantly and negatively related to tumor purity. Significant positive correlations with infiltrating levels of B cells, CD8+ T cells, CD4+ T cells,
macrophages, neutrophils and dendritic cells were observed with CFP expression. Genes highly expressed in the tumor microenvironment are expected to have
negative associations with tumor purity, while the opposite is likely to be true for genes highly expressed in the tumor cells.Frontiers in Immunology | www.frontiersin.org January 2021 | Volume 11 | Article 6149806
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patients, a higher expression of properdin positively correlated
with an OS (p < 0.05) (Figure 7A). According to the TIMER tool,
CFP gene expression moderately, but significantly and
negatively, correlated with the tumor purity (p < 0.05). It
revealed a partial but significant and positive correlation with
the levels of infiltrated B cells, CD8+ T cells, CD4+ T cells,
macrophages, neutrophils and dendritic cells (p < 0.05) (Figure
7B). The strength of the correlation was very weak for CD8+ T
cells, whereas it was weak for B cells, CD4+ T cells, macrophages,
neutrophils and dendritic cells. In the uterine cervical tissue,
immunohistochemical assessment for the presence of properdin
protein revealed a high expression in both the normal as well as
the tumoral tissues (Figure 8). Properdin appeared to be
diffusely expressed not only within the infiltrating cells
(macrophages and few cells of lymphoid morphology), but also
within the endothelial cells of small vessels located in the
subepithelial connective tissue.
Properdin in Pancreatic Adenocarcinoma
No significant difference regarding properdin expression level in
PAAD was detected as compared to normal pancreas using
various datasets (Data Not Shown). According to UALCAN
tool, no correlation between properdin mRNA expression and
OS rate was observed in patients with PAAD (Figure 9A).
However, when we used PROGgeneV2 tool, properdin mRNA
expression was found to be positively associated with an OS rateFrontiers in Immunology | www.frontiersin.org 7in PAAD patients (p < 0.05) (Figure 9B). With respect to
immune infiltration, CFP gene expression showed a partial but
significant and negative relationship with the tumor purity (p <
0.05). This means that properdin is unlikely to be expressed by
tumor cells but by the immune infiltrates. It suggested significant
positive partial correlations with infiltrating levels of B cells,
CD8+ T cells, CD4+ T cells, macrophages, neutrophils
and dendritic cells (p < 0.05) (Figure 9C). The strength of the
correlation was weak for B cells, CD8+ T cells and macrophages,
whereas it was found to be moderate for CD4+ T cells,
neutrophils and dendritic cells. IHC staining of the healthy
pancreatic tissue revealed that ~10% of acinar cells of the
exocrine part of pancreas had a high expression of properdin
(strong cytoplasmic labeling) (Figure 10A). The immune
infiltrate, consisting of scant macrophages present in the
connective tissue contexture also stained for properdin (Figure
10B). A marked expression of properdin by the infiltrating
immune cells, mostly consisting of macrophages and
granulocytes, was evident; however, we observed no properdin
expression in the neoplastic subclones (Figures 10C, D).DISCUSSION
The innate immunity plays a critical role in the protection against
cancer. The complement system is an important arsenal of the
innate immune system against pathogens as well as cancer. TheFIGURE 3 | Immunohistochemical evaluation of properdin in healthy lung and lung adenocarcinoma tissues. Representative microphotographs pertaining to
properdin expression in the alveolar macrophages (black arrows) and the endothelial cells (yellow arrows) in healthy pulmonary parenchyma (A, B). Representative
microphotographs of properdin staining detailing the presence of macrophages (green arrows) and granulocytes (red arrows) populating tumor infiltrates in lung
adenocarcinoma (LUAD) (C, D). Magnification 200 x (A–C), 400 x (B, D); scale bars 50 mm.January 2021 | Volume 11 | Article 614980
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antigens, and leads to increased deposition of complement
activation fragments on the surface of the tumor. C1q, for
instance, has been shown to bind to phospholipids of lung tumor
cell lines and evidence of activation of the classical pathway in
various cancer such as lung cancer, thyroid cancer, astrocytoma,
lymphoma, leukemia, and oropharyngeal cancer have been
reported (55, 56). C1q has recently been shown to be involved
in a range of pathophysiological functions that are not dependent
on complement activation. In fact, it is expressed in the
microenvironment of various types of human tumors, where it
can exert a protective or aharmful effect oncancer progression (57–
60). Similarly, in cases of acute lymphoblastic leukemia, Burkitt
lymphoma ormultiplemyeloma, dysregulation of the complement
alternative pathway has been reported (61). Exaggerated or
aberrant complement activation in the tumor microenvironment
has been shown to increase inflammation/infiltration via C5a.
Anti-tumor immune responses are stifled by the C5a-driven
recruitment of myeloid-derived suppressor cells, which support
tumorigenesis by upregulating anti-inflammatory (inhibitory)
molecules such as Programmed Death-Ligand 1 (PD-L1),
transforming growth factor-b (TGF-b) and IL-10 (62–64). C3a has
also been implicated in tumorigenesis; C3aR−/−mice show improved
disease outcome in melanoma (65). Factor H gene-deficient miceFrontiers in Immunology | www.frontiersin.org 8appear to develop spontaneous hepatocellular carcinoma with aging
(41). An in silico analysis appeared to suggest a protective role of
properdin in breast cancer by interacting with glycosaminoglycan
(GAG) structures on the tumor cell surface (39, 41, 66).
In the current study, we analyzed the prognostic value of
properdin, the positive regulator of the complement alternative
pathway, in four types of cancer, namely LUAD, LIHC, CESC, and
PAAD. The choice of the four tumors was made based on the
prognostic effect of properdin, which was assessed via UALCAN
using TCGA RNA-sequencing and patients’ clinical data from 33
different cancer types, including several metastatic tumors. Of the
33 cancers, properdin had a significant prognostic effect in only 4
neoplasms. Subsequently, CFP gene expression in various
neoplastic tissues was analyzed using Oncomine and UALCAN,
and comparedwith their healthy counterparts. Lower levels ofCFP
expression were observed in both LUAD and LIHC tissues
compared to their respective normal tissues. No significant
difference was observed in the expression levels in the case of
CESC andPAAD. Proteomic analysis of properdin levels in LUAD
was also analyzed by UALCAN and found to be lower in the
neoplastic tissue compared to the healthy tissues. However,
currently, proteomic analysis of the other three cancers are not
available on UALCAN. Kaplan–Meier survival analysis of LUAD,




FIGURE 4 | Properdin expression in liver hepatocellular carcinoma. In silico analysis of properdin (CFP) gene expression in liver hepatocellular carcinoma (LIHC). CFP
gene expression from Roessler (A), Roessler 2 (B), Wurmbach (C) Liver datasets plotted by Oncomine and The Cancer Genome Atlas (TCGA) Liver (D) dataset
plotted by UALCAN tool revealed a decrease in properdin mRNA expression in the adenocarcinoma tissues, when compared to the healthy liver tissues.January 2021 | Volume 11 | Article 614980
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FIGURE 5 | Prognostic effect of properdin on liver hepatocellular carcinoma. (A) The association between CFP expression and overall survival. Overall Survival (OS)
of liver cancer patients expressing high [red] (n=91) and low/medium [blue] (n=274) levels of properdin over a period of ~4,000 days (~11 years) analyzed with
Kaplan–Meier survival analysis using The Cancer Genome Atlas (TCGA) Liver dataset by UALCAN shows patients with high levels of properdin expression shows a
significant improvement in survival compared to their low/medium expression counterparts. (B) The correlation of CFP gene expression with immune infiltration level
in liver hepatocellular carcinoma. Levels of tumor-infiltrating immune cells in liver hepatocellular carcinoma were analyzed from TCGA Liver dataset using TIMER. CFP
expression was significantly negatively related to tumor purity. It showed significant positive correlations with infiltrating levels of B cells, CD8+ T cells and dendritic
cells. No significant correlation was evident with the infiltrating levels of CD4+ T cells, macrophages and neutrophils.Frontiers in Immunology | www.frontiersin.org January 2021 | Volume 11 | Article 6149809
Mangogna et al. Properdin and Cancer Prognosisexpression positively correlated with an OS rate of the patients. In
the case of PAAC, UALCAN survival analysis did not find any
correlation between themRNAexpression levels andOS; however,
analysis by PROGgeneV2 revealed a positive correlation between
mRNAexpression levels andOS.This variation canbe attributed to
the difference in the way the tools define patient cohorts, as both
tools use the same TCGA Pancreas dataset. UALCAN divides
patients into a high expression of properdin versus low/medium
expression. PROGgeneV2 divides patients at the median of gene
expression between the ones with low expression and those with
high expression. This is a limitation of the study involving
bioinformatics tools that can be used to evaluate the prognostic
implications of genes in various cancers. Thus, using the same
cohort of patients (for example, TCGA Pancreas dataset), the
results on the prognostic effect can differ, depending on whether
the court is divided by the median of expression or not.
It is highly plausible that the expression of the CFP gene
during tumorigenesis may lead to properdin export to the cell
surface (66), which may then promote phagocytosis byFrontiers in Immunology | www.frontiersin.org 10macrophages and dendritic cells (37, 38), in addition to
recruiting immune cells. Thus, the neoplastic cells have evolved
to express low levels of properdin, and hence, higher expression
of the protein leads to increased overall survival. Since TIICs are
independent predictors of sentinel lymph node status and
survival in cancer (67, 68), we investigated whether CFP
expression correlated with immune infiltration levels in various
cancer types. Tumor purity is defined as the proportion of cancer
cells in the tumor tissue or the percentage of cancer cells in a
solid tumor sample. CFP expression negatively correlated with
the tumor purity in all cancers. This suggests that the expression
of properdin likely occurs by the immune infiltrates and not by
the actual neoplastic cells. Infiltrating levels of B cells, CD8+ T
cells, CD4+ T cells, macrophages, neutrophils and dendritic cells
positively correlated in the case of LUAD, CESC and PAAD. In
the case of LIHC, a positive correlation with infiltrating levels of
B cells, CD8+ T cells and dendritic cells was observed, while no
significant correlation was observed between the expression of
CFP and the levels of infiltrating CD4+ T cells, macrophages andFIGURE 6 | Immunohistochemical analysis of properdin in normal liver and hepatocellular carcinoma tissues. Properdin immunohistochemistry (IHC) staining
showing the strong cytoplasmic expression by the hepatocytes in normal liver (black arrows) (A, B). Representative microphotographs detailing the macrophage-
associated tumor (green arrows) and a few neoplastic subclones (red arrow) expressing properdin in liver hepatocellular carcinoma (LIHC) (C, D). Magnification 200 x
(A–C), 400 x (B, D); scale bars 50 mm.January 2021 | Volume 11 | Article 614980
Mangogna et al. Properdin and Cancer PrognosisA
B
FIGURE 7 | Prognostic effect of properdin expression in cervical squamous cell carcinoma. (A) The association between CFP expression and overall survival. Overall
Survival (OS) of cervical squamous cell carcinoma (CESC) patients expressing high [green] (n=75) and low/medium [orange] (n=216) levels of properdin over a period
of ~7,000 days (~19 years), analyzed with Kaplan–Meier survival analysis using The Cancer Genome Atlas (TCGA) Cervix dataset by UALCAN, revealed that patients
with high levels of properdin expression had a significant improvement in survival compared to their low/medium expression counterparts. (B) The correlation of CFP
gene expression with immune infiltration level in cervical squamous cell carcinoma. Levels of tumor-infiltrating immune cells in cervical squamous cell carcinoma
(CESC) were analyzed from TCGA Cervix dataset using TIMER. CFP expression was significantly and negatively related to tumor purity. It had a significant positive
correlation with infiltrating levels of B cells, CD8+ T cells, CD4+ T cells, macrophages, neutrophils and dendritic cells. Genes highly expressed in the microenvironment
are expected to have negative association with tumor purity, while the opposite is the case for genes highly expressed in the tumor cells.Frontiers in Immunology | www.frontiersin.org January 2021 | Volume 11 | Article 61498011
Mangogna et al. Properdin and Cancer Prognosisneutrophils. These findings suggest that CFP plays a specific role
in immune infiltration in our carcinomas, in particular as regard
CD4+ T cells, neutrophils and dendritic cells. Therefore, CFP
could exert an important function in recruitment and regulation
of immune infiltrating cells in several carcinomas.
Interestingly, preliminary studies conducted in properdin
knock-out mice showed a difference in chemokine levels and
cell mobility in a tumor model (CM Stover, unpublished Data).
The role of immunecell infiltration in the tumormicroenvironment
and its consequences on tumor development is an intense area of
research: immune infiltration and cell phenotype polarization can
be a double-edged sword. It can promote or impede tumor growth,
and hence, overall survival. Given a positive correlation
with immune infiltration, the properdin expression levels reflect
the presence of immune cells that are less immunosuppressive
but can engage in the anti-tumor response. Another possibility
is that properdin acts as a balancing factor between macrophage
polarizationbetweenpro-inflammatoryM1andanti-inflammatory
M2 phenotypes (30). NK cells, a key player in the anti-tumor
immunity, have recently been shown to bind properdin throughFrontiers in Immunology | www.frontiersin.org 12NKp46 receptor (69). However, how properdin can impact on
NK cell-mediated properties in the tumor microenvironment
is unclear.
Anti-tumor immunity has been recently categorized intomainly
three phenotypes: immune-desert (immune ignorance), immune-
excluded (inhibitory chemokine/soluble factor-mediated), and
inflamed (where infiltration is immunosuppressive and/or
dysregulated) (70). The immune cell infiltration here includes
regulatory T cells, myeloid-derived suppressor cells, suppressor B
cells and fibroblasts. Tumor-infiltrating CD8+ T lymphocytes can
also be aberrantly active and immunologically exhausted. In a
recent study, Troiano et al. identified a specific subgroup of
squamous cell carcinoma of the oral tongue with poor prognosis
based on the density of tumor‐infiltrating lymphocytes
and localization (71). Thus, the tumor immune phenotyping
can be a better approach to stratify patients and decide on
precision medicine.
Understanding how the level of properdin expressed in the
tumor-infiltrating immune cells alters the tumormicroenvironment
and manipulates immune cells versus tumor cells should be of greatFIGURE 8 | Immunohistochemical analysis for properdin expression in uterine cervix and cervical squamous cell carcinoma. Representative images of macrophages
(black arrow), lymphoid cells (red arrow) and also the endothelial cells of vessels within the chorion (green arrow) expressing properdin in the healthy uterine cervix
(A, B) and CECS (C, D). Magnification 200 x (A–C), 400 x (B, D); scale bars 50 mm.January 2021 | Volume 11 | Article 614980
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FIGURE 9 | Prognostic significance of properdin in pancreatic adenocarcinoma. (A) The association between CFP expression and overall survival. Overall Survival
(OS) of pancreatic adenocarcinoma (PAAD) patients expressing high [red] (n=45) and low/medium [blue] (n=132) levels of properdin in the tissues over a period of
~3,000 days (~8 years) analyzed with Kaplan–Meier survival analysis using The Cancer Genome Atlas (TCGA). Pancreas dataset by UALCAN showed no correlation
between properdin expression levels and OS. (B) PROGgeneV2 analyzed OS association with CFP expression in PAAD patient tissues expressing high [red] (n=85)
and low/medium [green] (n=85) levels of properdin over a period of ~3,000 days (~8 years) using TCGA Pancreas dataset and showed significant improvement in
survival in patients expressing higher levels of properdin compared to their low/medium expressing counterparts. The variation in OS results can be attributed to the
way the tools define their patient cohorts. (C) The correlation between CFP gene expression and immune cell infiltration level in pancreatic adenocarcinoma. Levels of
tumor-infiltrating immune cells in PAAD were analyzed from TCGA Pancreas dataset using TIMER. CFP expression appeared to exhibit a significantly negative
correlation with tumor purity. There appeared to be a significant positive correlation with infiltrating levels of B cells, CD8+ T cells, CD4+ T cells, macrophages,
neutrophils and dendritic cells. Genes highly expressed in the tumor microenvironment are expected to have negative association with tumor purity, while the
opposite is likely to be case for genes highly expressed in the tumor cells.Frontiers in Immunology | www.frontiersin.org January 2021 | Volume 11 | Article 61498013
Mangogna et al. Properdin and Cancer Prognosisrelevance for immunotherapeutic development. Hence, further
study to examine the differential expression and distribution of
properdin along with immune cells in the neoplastic tissues is
urgently required. As properdin has also been shown to function in
a complement-independent manner (27, 28, 37), experiments in the
absence of the complement system and with an individual pathway
blocked must also be undertaken. In conclusion, our in-silico
analysis highlights a possible role of properdin as a novel marker
for tumor prognosis and increased survival in a range of cancers.DATA AVAILABILITY STATEMENT
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